Analystreport

Intellia Therapeutics (NASDAQ:NTLA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview